Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Ann Pharmacother ; 57(6): 637-645, 2023 06.
Artículo en Inglés | MEDLINE | ID: mdl-36168669

RESUMEN

BACKGROUND: Statins are expected to have beneficial effects on nonalcoholic fatty liver disease (NAFLD); however, evidence remains insufficient. OBJECTIVE: In this study, we aim to investigate the association between statin adherence and NAFLD development. METHODS: We conducted a nested case-control study of statin users using the Japan Medical Data Center administrative claims database (January 2005 to January 2020). Individuals who developed NAFLD were designated as cases. For each case, we randomly selected a maximum of 10 controls using risk set sampling. Good adherence was defined as the proportion of days covered (PDC) of ≥0.80. Higher intensity was defined as the median or higher of a cumulative defined daily dose (cDDD) per day covered by statin prescription. Conditional logistic regression analysis was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: In this study, 253 383 patients with the first statin prescription were identified. Of them, 7080 were selected and matched to 70 734 controls. The medians of PDC and intensity were 0.88 (interquartile range [IQR], 0.61-0.96) and 0.32 (IQR, 0.25-0.50) cDDD/day, respectively. Good adherence was significantly associated with a reduced risk of NAFLD development (adjusted OR, 0.82; 95% CI, 0.78-0.86). Higher intensity was not significantly associated with a reduced risk of NAFLD development (adjusted OR, 1.02; 95% CI, 0.97-1.08). CONCLUSION AND RELEVANCE: Good adherence to statins is associated with a reduced risk of NAFLD development, regardless of the statin intensity. Appropriate statin therapy could reduce the risk of NAFLD development.


Asunto(s)
Inhibidores de Hidroximetilglutaril-CoA Reductasas , Enfermedad del Hígado Graso no Alcohólico , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Enfermedad del Hígado Graso no Alcohólico/tratamiento farmacológico , Enfermedad del Hígado Graso no Alcohólico/epidemiología , Estudios de Casos y Controles , Pueblos del Este de Asia , Japón/epidemiología , Cumplimiento de la Medicación
2.
Int J Clin Pharmacol Ther ; 61(11): 492-502, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37644877

RESUMEN

OBJECTIVE: Pancreatic cancer-related mortality is increasing worldwide, and prevention methods and effective novel therapies are required. In pancreatic cancer, sodium-glucose cotransporters (SGLT) are involved in glucose uptake. This study aimed to clarify the association between SGLT2 inhibitors and pancreatic cancer development. MATERIALS AND METHODS: A nested case-control study was conducted using the JMDC administrative claims database (January 2005 to June 2020). Patients newly diagnosed with type 2 diabetes mellitus (T2DM) were included, and cases were defined as patients who developed pancreatic cancer. Patients with outcomes were randomly matched to a maximum of 20 controls according to age (± 5 years), sex, and calendar date (month and year) of the first T2DM diagnosis through risk set sampling. RESULTS: Of the 181,107 T2DM patients, 363 cases and 7,043 controls were selected with 14 and 457 patients prescribed SGLT2 inhibitors, respectively. Cumulative administration of SGLT2 inhibitors for > 180 days was significantly inversely associated with the development of pancreatic cancer (adjusted odds ratio: 0.58, 95% confidence interval: 0.31 - 0.99). CONCLUSION: SGLT2 inhibitors may reduce the risk of developing pancreatic cancer in T2DM patients. The number of patients over 65 years of age was small in this study due to the nature of the data source. Further studies with larger sample sizes including older patients are needed.


Asunto(s)
Diabetes Mellitus Tipo 2 , Neoplasias Pancreáticas , Inhibidores del Cotransportador de Sodio-Glucosa 2 , Humanos , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/epidemiología , Inhibidores del Cotransportador de Sodio-Glucosa 2/efectos adversos , Hipoglucemiantes/efectos adversos , Estudios de Casos y Controles , Pueblos del Este de Asia , Neoplasias Pancreáticas/tratamiento farmacológico , Neoplasias Pancreáticas/epidemiología , Neoplasias Pancreáticas/prevención & control , Glucosa , Sodio
3.
Support Care Cancer ; 30(2): 1765-1773, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-34595605

RESUMEN

PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event of cancer treatment; however, no drug is recommended for the prevention of CIPN. In Japan, several drugs such as Gosha-Jinki-Gan and duloxetine are frequently administered as a treatment for CIPN. The aim of this study was to elucidate prescription patterns of drugs administered for CIPN caused by oxaliplatin and the association between these drugs and the duration of oxaliplatin treatment. METHODS: We conducted a retrospective nationwide study using the JMDC administrative claims database (January 2005-June 2020; JMDC Inc., Japan). Patients newly treated with oxaliplatin were identified, and prescription patterns of CIPN medication including Gosha-Jinki-Gan, pregabalin, duloxetine, mecobalamin, and mirogabalin were investigated. The primary outcome was the duration of oxaliplatin treatment. Multivariable logistic regression analysis was performed to examine the association between CIPN medication and duration of oxaliplatin treatment. RESULTS: A total of 4,739 patients who newly received oxaliplatin were identified. Of these, 759 (16.0%) had received CIPN medication. Duloxetine was administered in 99 (2.1%) patients. Multivariable logistic regression analysis revealed that CIPN medication was significantly associated with the prolonged duration of oxaliplatin treatment (odds ratio: 2.35, [95% confidence interval: 1.99-2.77]). CONCLUSION: Real-world data demonstrated that the administration rate of CIPN medication was higher in patients who received oxaliplatin treatment for over 6 months.


Asunto(s)
Antineoplásicos , Enfermedades del Sistema Nervioso Periférico , Antineoplásicos/efectos adversos , Clorhidrato de Duloxetina/uso terapéutico , Humanos , Oxaliplatino/uso terapéutico , Enfermedades del Sistema Nervioso Periférico/inducido químicamente , Enfermedades del Sistema Nervioso Periférico/tratamiento farmacológico , Enfermedades del Sistema Nervioso Periférico/epidemiología , Estudios Retrospectivos
4.
Sensors (Basel) ; 22(24)2022 Dec 16.
Artículo en Inglés | MEDLINE | ID: mdl-36560302

RESUMEN

Personal mobility vehicles (PMVs) are compact and lightweight compared to automobiles; hence, human dynamic behavior affects a vehicle's postural stability. In this study, the dynamic behaviors of drivers of inverted pendulum vehicles (IPV) under manual and automatic driving were investigated. One particular feature of applying automatic driving to IPV is constant posture stabilization control. In this study, the drivers' center of gravity (COG)/center of foot pressure position (COP) and joint moments during turning were investigated experimentally. It was found that the drivers' COG shifted backward during turning and deceleration. For COP, it was found that drivers maintained balance by moving their inner foot more inward and their outer foot more outward during turning. These results are significant for understanding the steps taken to withstand centrifugal forces during turning. The joint moments of the foot were more significant in automatic turning than in manual turning to prevent falling owing to centrifugal force. These findings can facilitate the development of an automatic control method that shifts the COG of a driver, as in manual turning.


Asunto(s)
Conducción de Automóvil , Humanos , Automóviles , Aceleración , Orientación Espacial , Pie , Accidentes de Tránsito/prevención & control
5.
J Infect Chemother ; 27(3): 521-525, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33067106

RESUMEN

Syphilis has recently increased in prevalence in Japan. Neurosyphilis is a special pathological condition of syphilis well known to cause cerebral vasculitis and ischemic stroke. Neurosyphilis in the meningovascular stage rarely causes caliber irregularity of the cerebral blood vessels or cerebral hemorrhage. We describe the case of a 49-year-old Japanese man with neurosyphilis. Cerebral hemorrhage, multiple cerebral infarctions, and caliber irregularity of the cerebral blood vessels were observed, the patient underwent surgery for cerebral hemorrhage on the day of admission, all of which were suspected to be caused by syphilis. He was started on an antibacterial treatment of penicillin on the day of admission and was diagnosed with neurosyphilis the following week based on his serum and spinal fluid test results. His condition improved, and he was transferred to another hospital after 4 weeks of treatment consisting of 3 weeks of infusion treatment with benzylpenicillin followed by oral treatment with amoxicillin. To the best of our knowledge, this is a rare case of neurosyphilis in conjunction with cerebral hemorrhage and cerebral infarction. Clinicians should consider syphilis in the differential diagnosis of cerebral hemorrhage and cerebral infarction and test patients for sexually transmitted diseases, in addition to cerebrospinal fluid testing, when cerebral hemorrhage occurs with an unknown cause. This is especially pertinent when patients present with cerebral infarction or caliber irregularity of the cerebral blood vessels.


Asunto(s)
Hallazgos Incidentales , Neurosífilis , Infarto Cerebral/diagnóstico por imagen , Humanos , Hemorragias Intracraneales , Japón , Masculino , Persona de Mediana Edad , Neurosífilis/complicaciones , Neurosífilis/diagnóstico , Neurosífilis/tratamiento farmacológico
6.
Ann Pharmacother ; 54(10): 988-995, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-32186394

RESUMEN

BACKGROUND: Osteoporosis, which is a major public health concern, has been known to reduce health-related quality of life. Some studies have suggested that antipsychotics could perhaps cause osteoporosis by increasing serum prolactin levels. However, the association between antipsychotics and the risk for developing osteoporosis has been controversial. OBJECTIVE: The present study aimed to assess the association between antipsychotic use and onset of osteoporosis in real-world settings. METHODS: A multimethod data-mining approach using different algorithms and databases was used. First, disproportionality analysis was conducted using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database (2004-2017) with reporting odds ratio (ROR) and information component (IC) being used to indicate a signal. Furthermore, a sequence symmetry analysis using data from a large Japanese administrative claims database (2005-2017; JMDC Inc, Japan) was conducted. Short-term intervals (ie, 12, 24, and 36 months) were set to investigate the association between antipsychotic use and onset of osteoporosis using the adjusted sequence ratio (SR) to indicate a signal. RESULTS: No potential association between osteoporosis and all antipsychotics was observed in the FAERS database, except for perphenazine, which exhibited significant signals using both ROR and IC. Moreover, no potential association between osteoporosis and antipsychotics was observed in the JMDC claims database, except for sulpiride and aripiprazole. None of the antipsychotics indicated significant signals using all analyzed items (ROR, IC, and adjusted SR). CONCLUSION AND RELEVANCE: Real-world data show no association between antipsychotic use and the onset of osteoporosis. Further pharmacoepidemiological studies are needed for causality assessment.


Asunto(s)
Sistemas de Registro de Reacción Adversa a Medicamentos/estadística & datos numéricos , Antipsicóticos/uso terapéutico , Osteoporosis/epidemiología , Algoritmos , Antipsicóticos/administración & dosificación , Antipsicóticos/efectos adversos , Minería de Datos , Bases de Datos Factuales , Humanos , Oportunidad Relativa , Osteoporosis/sangre , Osteoporosis/etiología , Farmacovigilancia , Prolactina/sangre , Estados Unidos , United States Food and Drug Administration
7.
Int J Med Sci ; 17(4): 471-479, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32174777

RESUMEN

Introduction: Warfarin and direct oral anticoagulants (DOACs) have been widely used in antithrombotic therapy. Although warfarin use has been suspected to be associated with osteoporosis risk, several studies have shown otherwise. Conversely, a few reports have found an association between DOACs and osteoporosis. This study therefore clarifies the association between oral anticoagulants and osteoporosis by analyzing real-world data using different methodologies, algorithms, and databases. Methods: Real-world data from the US Food and Drug Administration Adverse Event Reporting System (FAERS; 2004-2016) and Japanese administrative claims database (2005-2017; JMDC Inc., Tokyo) were used. Reporting odds ratio (ROR) and information component (IC) were calculated through disproportionality analysis (DPA) using reports recorded in the FAERS. Sequence symmetry analysis (SSA) was employed to calculate the adjusted sequence ratio (SR) using the JMDC Claims Database. For the adjusted SR and ROR, a significant signal was detected when the lower limit of the two-sided 95% confidence interval (CI) was more than 1. For the IC, a significant signal was detected when the lower limit of the 95% CI was more than 0. Results: DPA for warfarin found significant signals for osteoporosis in ROR (1.43, 95% CI: 1.32-1.54) and IC (0.50, 95% CI: 0.39-0.61). SSA showed a significant association between warfarin use and osteoporosis or bisphosphonate use. Moreover, a significant association was observed in males and females, albeit only for warfarin. Conclusion: Multi-methodological data mining revealed that warfarin use, not DOACs, is significantly associated with osteoporosis regardless of sex difference.


Asunto(s)
Anticoagulantes/efectos adversos , Anticoagulantes/uso terapéutico , Osteoporosis/inducido químicamente , Osteoporosis/epidemiología , Sistemas de Registro de Reacción Adversa a Medicamentos , Intervalos de Confianza , Minería de Datos , Bases de Datos Factuales , Femenino , Humanos , Masculino , Caracteres Sexuales , Warfarina/efectos adversos , Warfarina/uso terapéutico
8.
Sci Rep ; 13(1): 11677, 2023 07 19.
Artículo en Inglés | MEDLINE | ID: mdl-37468563

RESUMEN

The association between statins and open-angle glaucoma (OAG) remains controversial. This study investigated the relationship between statins and OAG in Japanese patients with dyslipidemia using the Japanese administrative claims database. A nested case-control study using two models was conducted using the JMDC claims database (01/2005-01/2020). The onset of OAG: index date was defined as the diagnosis of glaucoma, prescription of anti-glaucoma drugs, or surgery of glaucoma. For each case, a maximum of 10 age-, sex-, and calendar year/month-matched controls were randomly selected by risk-set sampling with replacement. The number of statin prescriptions during the exposure assessment period, which was identified as the 12-month (model 1) or 24-month (model 2) periods prior to the index date, was used as an indicator for statin exposure. Adjusted odds ratios (aORs) and 95% confidence interval (CI) were estimated using conditional logistic regression analyses. We identified 375,373 patients with newly diagnosed dyslipidemia. Of these, 6180 cases and 61,792 controls (model 1) and 4153 cases and 41,522 controls (model 2) were selected. Statin use was not identified as a significant risk factor for OAG (model 1: aOR 0.98, 95% CI 0.93-1.03, model 2: aOR 0.97, 95% CI 0.91-1.04). Compared with nonexposure, short-term exposure (< 2 years) to statins was not related to an increased risk of OAG in the Japanese working-age population with dyslipidemia.


Asunto(s)
Glaucoma de Ángulo Abierto , Inhibidores de Hidroximetilglutaril-CoA Reductasas , Humanos , Estudios de Casos y Controles , Inhibidores de Hidroximetilglutaril-CoA Reductasas/efectos adversos , Estudios Retrospectivos , Glaucoma de Ángulo Abierto/inducido químicamente , Glaucoma de Ángulo Abierto/epidemiología , Glaucoma de Ángulo Abierto/diagnóstico , Pueblos del Este de Asia , Factores de Riesgo
9.
Ther Adv Musculoskelet Dis ; 13: 1759720X211047057, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34589142

RESUMEN

INTRODUCTION: Treatment of rheumatoid arthritis (RA) has advanced with the introduction of biological disease-modifying antirheumatic drugs. However, more than 20% of patients with RA still have moderate or severe disease activity. Hence, novel antirheumatic drugs are required. Recently, drug repurposing, a process of identifying new indications for existing drugs, has received great attention. Furthermore, a few reports have shown that antipsychotics are capable of affecting several cytokines that are also modulated by existing antirheumatic drugs. Therefore, we investigated the association between antipsychotics and RA by data mining using real-world data and bioinformatics databases. METHODS: Disproportionality and sequence symmetry analyses were employed to identify the associations between the investigational drugs and RA using the US Food and Drug Administration Adverse Event Reporting System (2004-2016) and JMDC administrative claims database (January 2005-April 2017; JMDC Inc., Tokyo, Japan), respectively. The reporting odds ratio (ROR) and information component (IC) were used in the disproportionality analysis to indicate a signal. The adjusted sequence ratio (SR) was used in the sequence symmetry analysis to indicate a signal. The bioinformatics analysis suite, BaseSpace Correlation Engine (Illumina, CA, USA) was employed to explore the molecular mechanisms associated with the potential candidates identified by the drug-repurposing approach. RESULTS: A potential inverse association between the antipsychotic haloperidol and RA, which exhibited significant inverse signals with ROR, IC, and adjusted SR, was found. Furthermore, the results suggested that haloperidol may exert antirheumatic effects by modulating various signaling pathways, including cytokine and chemokine signaling, major histocompatibility complex class-II antigen presentation, and Toll-like receptor cascade pathways. CONCLUSION: Our drug-repurposing approach using data mining techniques identified haloperidol as a potential antirheumatic drug candidate.

10.
ACS Omega ; 6(30): 19642-19646, 2021 Aug 03.
Artículo en Inglés | MEDLINE | ID: mdl-34368551

RESUMEN

3-Decyl-ß-proline, which has a highly lipophilic substituent, was synthesized, and its catalytic activities in Michael addition using water as the solvent were investigated. The decyl substituent promoted the reaction by hydrophobic interactions to afford the Michael adduct in a high yield and with high diastereoselectivity under low catalyst loading.

11.
Nihon Jibiinkoka Gakkai Kaiho ; 112(11): 752-6, 2009 Nov.
Artículo en Japonés | MEDLINE | ID: mdl-19999153

RESUMEN

We report a case of Langerhans cell histiocytosis (LCH), a rare disease caused by the proliferation of abnormal Langerhans cells, coincident with severe external ear canal inflammation. A 27-year-old man with a 1-year history of external ear canal discharge was found in computed tomography (CT) to have left temporal bone erosion with tissue granulation. Chest X-ray showed pulmonary fibrosis, necessitating transbronchial lung biopsy that yielded a definitive diagnosis of multisystem, multisite LCH involving the bone, skin, lung, pituitary, thyroid, and lymph node systems. He underwent combination chemotherapy directed by the Japan LCH Study Group. LCH should therefore be considered in the case of a patient with severe external ear canal inflammation coincident with temporal bone erosion.


Asunto(s)
Conducto Auditivo Externo , Histiocitosis de Células de Langerhans/diagnóstico , Adulto , Enfermedades del Oído/etiología , Histiocitosis de Células de Langerhans/complicaciones , Humanos , Inflamación , Masculino
12.
Sci Rep ; 9(1): 16597, 2019 11 12.
Artículo en Inglés | MEDLINE | ID: mdl-31719612

RESUMEN

Cardiac glycosides, such as digoxin, inhibit Na+/K+-ATPases and cause secondary activation of Na+/Ca2+ exchangers. Preclinical investigations have suggested that digoxin may have anticancer properties. In order to clarify the functional mechanisms of digoxin in cancer, we performed an integrative analysis of clinical and bioinformatics databases. The US Food and Drug Administration Adverse Event Reporting System and the Japan Medical Data Center claims database were used as clinical databases to evaluate reporting odds ratios and adjusted sequence ratios, respectively. The BaseSpace Correlation Engine and Connectivity Map bioinformatics databases were used to investigate molecular pathways related to digoxin anticancer mechanisms. Clinical database analyses suggested an inverse association between digoxin and four cancers: gastric, colon, prostate and haematological malignancy. The bioinformatics database analysis suggested digoxin may exert an anticancer effect via peroxisome proliferator-activated receptor α and apoptotic caspase cascade pathways. Our integrative analysis revealed the possibility of digoxin as a drug repositioning candidate for cancers.


Asunto(s)
Antineoplásicos/farmacología , Biología Computacional/métodos , Bases de Datos Factuales , Digoxina/farmacología , Reposicionamiento de Medicamentos , Neoplasias/tratamiento farmacológico , Cardiotónicos/farmacología , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA